Consumer Product Developed for Male Climax Control

Apr 11, 2001, 01:00 ET from IDIST Laboratories, LLC

    DOVER, Del., April 11 /PRNewswire/ -- IDIST Laboratories, LLC announced
 today that it has released for consumer purchase a product that helps promote
 greater climax (ejaculatory) control in men and allows longer-lasting and more
 mutually satisfying sexual intercourse.  Deferol(TM) Climax Control Supplement
 is a patent pending, clinically tested product that is the first science-based
 consumer product to be introduced as a male climax control supplement.
     Early ejaculation, premature ejaculation (PE), and lack of ejaculatory
 control are reported to be the most common sexual difficulties in men.
 According to "American Family Physician," "up to 40% of U.S. males have
 difficulties with premature ejaculation (PE) or lack of ejaculatory control at
 some time in their lives."  Other surveys have reported that between 30-60% of
 men have intermittent concerns about ejaculating too rapidly.  Currently,
 there is no FDA-approved prescription drug for the treatment of premature
 ejaculation or climax control problems.
     "This is a very significant problem affecting at least one-third of all
 sexually active men," stated Christopher P. Steidle, M.D., a urologist and
 leading sexual medicine researcher with Northeast Indiana Research in Fort
 Wayne.  Dr. Steidle is the author of "The Impotence Sourcebook,
 Testosterone -- A Users Manual" and author of the WellnessWeb.com article
 "Ejaculatory Disorders."  "Until the availability of Deferol(TM), the only
 useful alternative physicians had to offer men with ejaculatory control
 problems was to prescribe SSRI-type anti-depressant drugs on an off-label
 basis.  Like Deferol(TM), these prescription anti-depressant drugs work by
 increasing brain serotonin and decreasing anxiety, however, the prescription
 drugs are not without their drawbacks," said Dr. Steidle.
     As with other types of sexual problems, early ejaculation and a lack of
 ejaculatory control can cause significant stress and dissatisfaction for both
 partners and may be disruptive to marriages and other relationships.  "A
 surprising percentage of women complain to their physicians that their partner
 is unable to perform sexual intercourse for a satisfactory amount of time,"
 said Dr. Steidle, also co-author of "The Female Sexual Dysfunction
 Treatments."  "A man's lack of ejaculatory control can sometimes undermine an
 otherwise healthy relationship."
     Pilot consumer studies were conducted last year with both "on-demand"
 (when needed), and chronic daily use of Deferol(TM).  In those studies, the
 intravaginal latency period for ejaculation (time to climax during
 intercourse) was significantly improved after use of Deferol(TM).  David M.
 Ferguson, Ph.D., M.D., in collaboration with a group of urologists nationwide,
 plans to conduct additional studies with Deferol(TM).  Dr. Ferguson is a
 prominent medical researcher in Chicago specializing in clinical trial
 protocol development and has substantial expertise in both male and female
 sexual medicine research.
     "There is strong scientific evidence in the medical literature that
 supports the Deferol(TM) formulation which, by design, utilizes the same
 proven pathway that prescription SSRI anti-depressants use as part of its
 activity," said Dr. Ferguson.  "Independent animal laboratory studies have
 already demonstrated that ingredients in Deferol(TM) significantly delay time
 to ejaculation."
     Deferol(TM) was formulated by pharmacists, pharmaceutical scientists, and
 sexual health researchers, holding U.S. and international patents involving
 serotonin, to address the principal factors that contribute to a lack of
 ejaculatory control in men.  "Unlike anti-depressants, Deferol(TM) was
 designed to briefly, but naturally, elevate central levels of serotonin and
 also deliver a specific natural anti-anxiety compound," said Martin G. Crosby,
 R.Ph., co-inventor of Deferol(TM).  "Together, the proprietary combination of
 ingredients in Deferol(TM) helps to significantly improve ejaculatory control
 and combat the anxiety that can cause early ejaculation.  Deferol's unique
 formulation helps control male sexual climax in a safe, non-prescription
 manner."
     Deferol(TM) is now available to consumers via a confidential purchasing
 procedure through the Company's website and through a highly respected
 consumer health website.  Both websites have extensive patient education
 materials about premature ejaculation and lack of ejaculatory control.
 Because Deferol(TM) is a supplement, obtaining it does not require visiting a
 physician or obtaining a prescription.  For more information or to purchase
 Deferol(TM), please visit www.deferol.com, www.wellnessweb.com, or call
 1-800-213-0300.
 
     About IDIST Laboratories, LLC
     IDIST Laboratories, LLC is a science-based consumer products company
 engaged in commercializing innovative proprietary consumer products to improve
 quality of life for men and women, with an initial strategic focus on sexual
 health issues.  In addition to Deferol(TM) Climax Control Supplement, the
 Company's current product development pipeline includes a series of
 proprietary sexual health and sexual enhancement consumer products.  In the
 United States, to complement the company's internal website distribution
 channel www.deferol.com, the Company has partnered with a leading healthcare
 website, www.wellnessweb.com.  Internationally, the Company intends to partner
 with existing multi-national distributors to market and distribute Deferol(TM)
 and its additional pipeline products to optimize global consumer access.
     IDIST Laboratories, LLC applauds the efforts of pharmaceutical companies
 such as Eli Lilly & Company, PPD GenuPro, Vivus, and others working to develop
 oral prescription -- only SSRI anti-depressant compounds to treat premature
 ejaculation.  Deferol(TM) Climax Control Supplement is not a drug, and the
 statements in this press release have not been evaluated by the FDA.
 Deferol(TM) Climax Control Supplement is not intended to diagnose, treat,
 cure, or prevent any disease.  Deferol(TM) Climax Control Supplement is a
 unique natural formulation intended to promote greater climax control in men
 and allow for longer-lasting sex.
 
 

SOURCE IDIST Laboratories, LLC
    DOVER, Del., April 11 /PRNewswire/ -- IDIST Laboratories, LLC announced
 today that it has released for consumer purchase a product that helps promote
 greater climax (ejaculatory) control in men and allows longer-lasting and more
 mutually satisfying sexual intercourse.  Deferol(TM) Climax Control Supplement
 is a patent pending, clinically tested product that is the first science-based
 consumer product to be introduced as a male climax control supplement.
     Early ejaculation, premature ejaculation (PE), and lack of ejaculatory
 control are reported to be the most common sexual difficulties in men.
 According to "American Family Physician," "up to 40% of U.S. males have
 difficulties with premature ejaculation (PE) or lack of ejaculatory control at
 some time in their lives."  Other surveys have reported that between 30-60% of
 men have intermittent concerns about ejaculating too rapidly.  Currently,
 there is no FDA-approved prescription drug for the treatment of premature
 ejaculation or climax control problems.
     "This is a very significant problem affecting at least one-third of all
 sexually active men," stated Christopher P. Steidle, M.D., a urologist and
 leading sexual medicine researcher with Northeast Indiana Research in Fort
 Wayne.  Dr. Steidle is the author of "The Impotence Sourcebook,
 Testosterone -- A Users Manual" and author of the WellnessWeb.com article
 "Ejaculatory Disorders."  "Until the availability of Deferol(TM), the only
 useful alternative physicians had to offer men with ejaculatory control
 problems was to prescribe SSRI-type anti-depressant drugs on an off-label
 basis.  Like Deferol(TM), these prescription anti-depressant drugs work by
 increasing brain serotonin and decreasing anxiety, however, the prescription
 drugs are not without their drawbacks," said Dr. Steidle.
     As with other types of sexual problems, early ejaculation and a lack of
 ejaculatory control can cause significant stress and dissatisfaction for both
 partners and may be disruptive to marriages and other relationships.  "A
 surprising percentage of women complain to their physicians that their partner
 is unable to perform sexual intercourse for a satisfactory amount of time,"
 said Dr. Steidle, also co-author of "The Female Sexual Dysfunction
 Treatments."  "A man's lack of ejaculatory control can sometimes undermine an
 otherwise healthy relationship."
     Pilot consumer studies were conducted last year with both "on-demand"
 (when needed), and chronic daily use of Deferol(TM).  In those studies, the
 intravaginal latency period for ejaculation (time to climax during
 intercourse) was significantly improved after use of Deferol(TM).  David M.
 Ferguson, Ph.D., M.D., in collaboration with a group of urologists nationwide,
 plans to conduct additional studies with Deferol(TM).  Dr. Ferguson is a
 prominent medical researcher in Chicago specializing in clinical trial
 protocol development and has substantial expertise in both male and female
 sexual medicine research.
     "There is strong scientific evidence in the medical literature that
 supports the Deferol(TM) formulation which, by design, utilizes the same
 proven pathway that prescription SSRI anti-depressants use as part of its
 activity," said Dr. Ferguson.  "Independent animal laboratory studies have
 already demonstrated that ingredients in Deferol(TM) significantly delay time
 to ejaculation."
     Deferol(TM) was formulated by pharmacists, pharmaceutical scientists, and
 sexual health researchers, holding U.S. and international patents involving
 serotonin, to address the principal factors that contribute to a lack of
 ejaculatory control in men.  "Unlike anti-depressants, Deferol(TM) was
 designed to briefly, but naturally, elevate central levels of serotonin and
 also deliver a specific natural anti-anxiety compound," said Martin G. Crosby,
 R.Ph., co-inventor of Deferol(TM).  "Together, the proprietary combination of
 ingredients in Deferol(TM) helps to significantly improve ejaculatory control
 and combat the anxiety that can cause early ejaculation.  Deferol's unique
 formulation helps control male sexual climax in a safe, non-prescription
 manner."
     Deferol(TM) is now available to consumers via a confidential purchasing
 procedure through the Company's website and through a highly respected
 consumer health website.  Both websites have extensive patient education
 materials about premature ejaculation and lack of ejaculatory control.
 Because Deferol(TM) is a supplement, obtaining it does not require visiting a
 physician or obtaining a prescription.  For more information or to purchase
 Deferol(TM), please visit www.deferol.com, www.wellnessweb.com, or call
 1-800-213-0300.
 
     About IDIST Laboratories, LLC
     IDIST Laboratories, LLC is a science-based consumer products company
 engaged in commercializing innovative proprietary consumer products to improve
 quality of life for men and women, with an initial strategic focus on sexual
 health issues.  In addition to Deferol(TM) Climax Control Supplement, the
 Company's current product development pipeline includes a series of
 proprietary sexual health and sexual enhancement consumer products.  In the
 United States, to complement the company's internal website distribution
 channel www.deferol.com, the Company has partnered with a leading healthcare
 website, www.wellnessweb.com.  Internationally, the Company intends to partner
 with existing multi-national distributors to market and distribute Deferol(TM)
 and its additional pipeline products to optimize global consumer access.
     IDIST Laboratories, LLC applauds the efforts of pharmaceutical companies
 such as Eli Lilly & Company, PPD GenuPro, Vivus, and others working to develop
 oral prescription -- only SSRI anti-depressant compounds to treat premature
 ejaculation.  Deferol(TM) Climax Control Supplement is not a drug, and the
 statements in this press release have not been evaluated by the FDA.
 Deferol(TM) Climax Control Supplement is not intended to diagnose, treat,
 cure, or prevent any disease.  Deferol(TM) Climax Control Supplement is a
 unique natural formulation intended to promote greater climax control in men
 and allow for longer-lasting sex.
 
 SOURCE  IDIST Laboratories, LLC